Management of Bradycardia and Hypertension in Patients on Beta-Blockers

Current Medication Assessment

• The European Heart Journal recommends that bradycardia is a specific contraindication for beta-blocker therapy in patients 2, 3
• The patient is experiencing bradycardia, which is a known adverse effect of beta-blockers like metoprolol, according to Circulation 1

Recommended Medication Changes

For Bradycardia Management:

• The European Heart Journal suggests reducing or discontinuing metoprolol as it is the likely cause of the bradycardia, and symptomatic bradycardia is listed as a contraindication to beta-blocker therapy in patients 2, 1, 3
• If beta-blocker therapy is still desired despite bradycardia, a very low dose with careful monitoring could be attempted, as recommended by the European Heart Journal 2

Implementation Strategy

• The European Heart Journal and Circulation recommend reducing metoprolol dose by 50% and monitoring heart rate response, then reassessing heart rate and blood pressure within 1-2 weeks of medication changes 2, 1, 4

Monitoring Parameters

• The American Heart Association, as published in Circulation, targets a heart rate of >60 bpm 1
• The European Journal of Heart Failure recommends monitoring for symptoms of hypotension during medication adjustments 4
• The European Journal of Heart Failure also suggests reassessing heart rate and blood pressure within 1-2 weeks of medication changes 4

Important Considerations and Caveats

• The European Heart Journal recommends that if the patient has underlying heart failure or coronary artery disease, cardiology consultation may be warranted before discontinuing beta-blocker therapy 2
• The European Journal of Heart Failure suggests that if blood pressure remains uncontrolled after losartan adjustment, consider adding a calcium channel blocker or diuretic rather than continuing beta-blocker therapy in the setting of bradycardia 4